UY30477A1 - Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina - Google Patents
Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteinaInfo
- Publication number
- UY30477A1 UY30477A1 UY30477A UY30477A UY30477A1 UY 30477 A1 UY30477 A1 UY 30477A1 UY 30477 A UY30477 A UY 30477A UY 30477 A UY30477 A UY 30477A UY 30477 A1 UY30477 A1 UY 30477A1
- Authority
- UY
- Uruguay
- Prior art keywords
- bipirimidinil
- diamine
- derivatives
- protein kinase
- kinase inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83049206P | 2006-07-12 | 2006-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30477A1 true UY30477A1 (es) | 2009-04-30 |
Family
ID=38617203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY30477A UY30477A1 (es) | 2006-07-12 | 2007-07-11 | Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8026243B2 (enExample) |
| EP (1) | EP2044036B1 (enExample) |
| JP (1) | JP2009543798A (enExample) |
| KR (1) | KR20090029832A (enExample) |
| CN (1) | CN101511798B (enExample) |
| AR (1) | AR061867A1 (enExample) |
| AT (1) | ATE508119T1 (enExample) |
| AU (1) | AU2007272646A1 (enExample) |
| BR (1) | BRPI0714291A2 (enExample) |
| CA (1) | CA2657381A1 (enExample) |
| CL (1) | CL2007002017A1 (enExample) |
| DE (1) | DE602007014374D1 (enExample) |
| ES (1) | ES2367666T3 (enExample) |
| MX (1) | MX2009000429A (enExample) |
| PE (1) | PE20080548A1 (enExample) |
| PL (1) | PL2044036T3 (enExample) |
| PT (1) | PT2044036E (enExample) |
| RU (1) | RU2009104340A (enExample) |
| TW (1) | TW200811134A (enExample) |
| UY (1) | UY30477A1 (enExample) |
| WO (1) | WO2008008747A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
| CN101679409B (zh) | 2006-12-22 | 2014-11-26 | Astex治疗学有限公司 | 双环杂环衍生化合物、其医药组合物和其用途 |
| AU2007337886C1 (en) | 2006-12-22 | 2014-10-16 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
| CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AR086992A1 (es) | 2011-06-20 | 2014-02-05 | Bayer Ip Gmbh | Tienilpiri(mi)dinilpirazoles |
| EP2763987B1 (en) | 2011-10-06 | 2018-07-18 | Bayer CropScience AG | Heterocyclylpyri(mi)dinylpyrazole as fungicidals |
| PL2763993T3 (pl) | 2011-10-06 | 2017-09-29 | Bayer Intellectual Property Gmbh | Heterocyklilopiry(mi)dynylopirazol |
| IN2014KN02601A (enExample) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| SI2861595T1 (sl) | 2012-06-13 | 2017-04-26 | Incyte Holdings Corporation | Substituirane triciklične spojine kot inhibitorji fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| EP2902489B9 (en) * | 2012-09-27 | 2018-02-07 | Chugai Seiyaku Kabushiki Kaisha | Fgfr3 fusion gene and pharmaceutical drug targeting same |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| SMT201900107T1 (it) | 2013-03-12 | 2019-02-28 | Vertex Pharma | Inibitori della dna-pk |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
| MX369646B (es) | 2014-08-18 | 2019-11-15 | Eisai R&D Man Co Ltd | Sal de derivado de piridina monociclico y su cristal. |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| WO2016152907A1 (ja) | 2015-03-25 | 2016-09-29 | 国立研究開発法人国立がん研究センター | 胆管癌治療剤 |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR102613433B1 (ko) * | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
| WO2019189241A1 (ja) | 2018-03-28 | 2019-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌治療剤 |
| KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| PL3788047T3 (pl) | 2018-05-04 | 2025-04-14 | Incyte Corporation | Stałe postacie inhibitora fgfr i sposoby ich otrzymywania |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| KR102133595B1 (ko) | 2019-05-31 | 2020-07-13 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR102112336B1 (ko) | 2019-08-12 | 2020-05-18 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| MXPA05012281A (es) | 2003-05-14 | 2006-05-19 | Torreypines Therapeutics Inc | Compuestos y uso de los mismos en la modulacion beta amiloide. |
| EP1670771A4 (en) | 2003-09-30 | 2010-09-01 | Irm Llc | COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES |
| CA2564355C (en) | 2004-05-07 | 2012-07-03 | Amgen Inc. | Protein kinase modulators and method of use |
| WO2007092531A2 (en) | 2006-02-06 | 2007-08-16 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2007
- 2007-07-04 TW TW096124311A patent/TW200811134A/zh unknown
- 2007-07-10 RU RU2009104340/04A patent/RU2009104340A/ru not_active Application Discontinuation
- 2007-07-10 KR KR1020097002815A patent/KR20090029832A/ko not_active Withdrawn
- 2007-07-10 EP EP07812739A patent/EP2044036B1/en not_active Not-in-force
- 2007-07-10 DE DE602007014374T patent/DE602007014374D1/de active Active
- 2007-07-10 CA CA002657381A patent/CA2657381A1/en not_active Abandoned
- 2007-07-10 AU AU2007272646A patent/AU2007272646A1/en not_active Abandoned
- 2007-07-10 MX MX2009000429A patent/MX2009000429A/es not_active Application Discontinuation
- 2007-07-10 PT PT07812739T patent/PT2044036E/pt unknown
- 2007-07-10 PE PE2007000885A patent/PE20080548A1/es not_active Application Discontinuation
- 2007-07-10 AR ARP070103061A patent/AR061867A1/es unknown
- 2007-07-10 BR BRPI0714291-9A2A patent/BRPI0714291A2/pt not_active Application Discontinuation
- 2007-07-10 WO PCT/US2007/073111 patent/WO2008008747A1/en not_active Ceased
- 2007-07-10 PL PL07812739T patent/PL2044036T3/pl unknown
- 2007-07-10 JP JP2009519623A patent/JP2009543798A/ja active Pending
- 2007-07-10 US US12/373,441 patent/US8026243B2/en not_active Expired - Fee Related
- 2007-07-10 ES ES07812739T patent/ES2367666T3/es active Active
- 2007-07-10 AT AT07812739T patent/ATE508119T1/de active
- 2007-07-10 CN CN2007800337140A patent/CN101511798B/zh not_active Expired - Fee Related
- 2007-07-11 UY UY30477A patent/UY30477A1/es not_active Application Discontinuation
- 2007-07-11 CL CL200702017A patent/CL2007002017A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101511798A (zh) | 2009-08-19 |
| PL2044036T3 (pl) | 2011-09-30 |
| TW200811134A (en) | 2008-03-01 |
| EP2044036A1 (en) | 2009-04-08 |
| RU2009104340A (ru) | 2010-08-20 |
| BRPI0714291A2 (pt) | 2014-10-21 |
| JP2009543798A (ja) | 2009-12-10 |
| ATE508119T1 (de) | 2011-05-15 |
| EP2044036B1 (en) | 2011-05-04 |
| PE20080548A1 (es) | 2008-06-24 |
| CN101511798B (zh) | 2011-11-02 |
| CA2657381A1 (en) | 2008-01-17 |
| PT2044036E (pt) | 2011-08-23 |
| ES2367666T3 (es) | 2011-11-07 |
| AR061867A1 (es) | 2008-09-24 |
| KR20090029832A (ko) | 2009-03-23 |
| DE602007014374D1 (de) | 2011-06-16 |
| MX2009000429A (es) | 2009-01-29 |
| AU2007272646A1 (en) | 2008-01-17 |
| WO2008008747A1 (en) | 2008-01-17 |
| CL2007002017A1 (es) | 2008-06-13 |
| US8026243B2 (en) | 2011-09-27 |
| US20100234376A1 (en) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30477A1 (es) | Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina | |
| ECSP23004573A (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| GT200600028A (es) | Compuestos y composiciones como inhibidores de proteina kinasa | |
| CL2008003798A1 (es) | Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades. | |
| CR10566A (es) | Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos | |
| CL2008003096A1 (es) | Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras. | |
| UY30500A1 (es) | Compuestos de azabencimidazolilo | |
| SV2004001691A (es) | Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen compuestos y sus usos | |
| ECSP099414A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa | |
| NI201000193A (es) | Formulaciones orales de análogos de citidina y métodos de uso de las mismas. | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| UY28955A1 (es) | Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos | |
| ECSP099378A (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| CO6321136A2 (es) | Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p) | |
| CR11264A (es) | Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
| ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CO6361936A2 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
| DOP2010000134A (es) | Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos | |
| ECSP066734A (es) | Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos | |
| UY31922A (es) | Compuestos | |
| UY30220A1 (es) | Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo | |
| CL2010001362A1 (es) | Forma de dosificacion farmaceutica para la liberacion inmediata de la sustancia activa 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato; y su uso para el tratamiento y/o prevencion de enfermedades oncologicas e inmunologicas, entre otras. | |
| DOP2011000134A (es) | Lactamas como inhibidores de beta secretasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20170721 |